Corporate Counsel
  • Home
  • News
  • Surveys
  • Resources
  • Lawjobs
  • Advertise
  • Subscribe
  • Bookstore
  • Contact

Topics » IP Insider | Labor & Employment | From the Experts | On the Job | Moves | DC Watch | International

Home > Bayer Sues in U.S. to Stop India Generic Drug Co.

Font Size: increase font decrease font

Bayer Sues in U.S. to Stop India Generic Drug Co.

By Lisa Shuchman Contact All Articles 

Corporate Counsel

March 19, 2013

  •    
  •    
  •    
  •      
 
bayer_logo

Related Items

  • India Patent Ruling on Cancer Drug a Blow to Bayer AG

A subsidiary of Bayer AG, the Germany-based pharmaceutical company, has filed suit [PDF] in federal court in Wilmington, Delaware, against Glenmark Generics, an international generic drug manufacturer, seeking to stop the Mumbai-based company from selling a generic form of a medication used to treat a skin disorder.

Glenmark applied for U.S. Food and Drug Administration approval for a generic version of Finacea, a gel use to treat the skin condition rosacea. But the Bayer subsidiaries Intendis and Intraserv said they will suffer "irreparable harm for which they have no adequate remedy at law" if Glenmark is allowed to manufacture and sell the drug before Bayer’s patent (United States Patent NO. 6,534,070, known as the ’070 patent) expires in 2018.

The lawsuit, filed under provisions of the Hatch-Waxman Act, automatically triggers a stay of final FDA approval of Glenmark’s “Abbreviated New Drug Application” (ANDA) for up to 30 months or until final resolution of the matter before the court, whichever occurs first.

According to the complaint, Glenmark sent a notice letter to Intendis and Bayer in January informing them that an ANDA had been filed with the FDA and claiming that the ANDA product “would not infringe any claims of the ‘070 patent.”

But the Bayer subsidiaries said in the complaint that the generic “is an act of infringement of one or more claims of the ‘070 patent.” They ask that the Delaware court issue a judgment and order prohibiting Glenmark from making, using, selling, or importing the generic product.

Glenmark’s application is for its own version of azeliac acid gel, which is approved for the treatment of inflammatory papules and pustules of mild to moderate rosacea —a chronic skin condition that mainly affects the face.

Glenmark said in a statement it believes it may be a “first applicant” to file an ANDA for the generic version of Finacea and may be entitled to 180 days of generic market exclusivity. This would give the company an advantage over its competitors in the generic drug space, as its product would be the only generic available during that time.

Finacea had U.S. sales of about $95 million for the 12 months ending September 30, 2012, according to data compiled by IMS Health, a provider of health-care information, Glenmark said.

Glenmark is one of several generic manufacturers that recently lost a challenge to AstraZeneca, which had its patent for cholesterol drug Crestor upheld by an appeals court until its expiration in 2016.

Calls to Bradford Badke and Michael Kahn of Ropes & Gray, who are of counsel to the Bayer subsidiaries, and to Rodger Smith II of Morris, Nichols, Arsht & Tunnel, who authored the complaint, were not immediately returned.



Subscribe to Corporate Counsel

You must be signed in to comment on an article

Find similar content

Firms mentioned

    
  • Ropes & Gray

Companies, agencies mentioned

    
  • Intendis
  • AstraZeneca plc
  • Food & Drug Administration
  • Ims Health Inc.
  • Bayer AG

Most viewed stories

    
  1. Managing Relationships With Legal Project Management
    •      
  2. Best Legal Departments 2013
    •      
  3. Taking the Reins of Legal Department Operations
    •      
  4. Cloud Computing and Unexpected FCPA Jurisdiction
    •      
  5. Hiring Summer Interns? Make Sure You Do it Right
    •      
lawjobs.com

TOP JOBS

MORE JOBS

POST A JOB

From the Law.com Network

Hiring Interns? Be Sure to Do It Right

ACC Weighs in on Arizona's In-House Pro Bono Rules

Ex-Dewey Partners Face New Foe in Firm's Bankruptcy

S&C Adds Linklaters Restructuring Partner in London
  •      
    • Subscription Required

Contrite Companies Can Win Forgiveness in Bribery Cases
  •      
    • Subscription Required

Plaintiffs Want to See Toyota's 'Crown Jewels'
  •      
    • Subscription Required

Enron Sandbox Stirs Up Private Data, Again

LegalTech West Coast Wraps Up With Ethics, VC News

In Tricky Prosecutions, Judges Play Peacemakers

Ropers Majeski Tries to Re-Invent Itself
  •      
    • Subscription Required

Fla. Attorneys Lead Force-Placed Insurance Fight

Lawsuit Names Missing Fla. Attorney for Alleged Fraud
  •      
    • Subscription Required

Summer Programs Still in a Drought

Lawyer Not Covered for Alleged Malpractice at Prior Firm
  •      
    • Subscription Required

The Affordable State-Specific Practice Solution
Available in NY, NJ, PA and CT editions - research, draft and prepare even the most complex cases with ease.

Firm Takes Another Hit in Bid for 'Unconscionable' Fees

New York's Martin Act Faces Test in Challenge to 2005 Case

Castille Testifies in Favor of 'Civil Gideon' Funding

Workers' Comp Judges Can't Fight Rescinded Raise
  •      
    • Subscription Required

Law Schools Are Looking Beyond LSATs, Says Mich. Dean

Is Freezing Your Eggs the Solution?

Advising Clients on Weather and the Workplace
  •      
    • Subscription Required

Texas Sues BP, Others Over Deepwater Oil Spill Disaster
  •      
    • Subscription Required

'Follow That Escapee!'

Judge Who Tossed Defense Counsel Accused of 'Partiality'
  •      
    • Subscription Required

Corporate Bribery Case Part Of National Trend
  •      
    • Subscription Required

Court Continues To Grant Lawyers Fraud Immunity
  •      
    • Subscription Required

  • About Corporate Counsel   |
  • Contact Corporate Counsel   |
  • Advertise with Us   |
  • Sitemap
  • About |
  • ALM Properties |
  • ALM Reprints |
  • Customer Support |
  • Privacy Policy |
  • Terms & Conditions |
  • ALM User License Agreement
ALM Media